ORAFIX (Risedronate) is an inhibitor of osteoclast-mediated bone resorption agent.
Each film-coated tablet contains Sodium Risedronate 150 mg.
Prevention and treatment of osteoporosis in postmenopausal women:
In the treatment of osteoporosis Orafix increases bone mass and prevents fractures, including hip, wrist and spine fractures. Bone loss is particularly rapid in post-menopausal women under 60. Associated risk factors include: thin, early menopause, Caucasian or Asian race, family history of osteoporosis.
The administration of Orafix must be associated with an adequate intake of Calcium and Vitamin D.
1 coated tablet 150 mg Sodium Risedronate.